Should clinicians be concerned about the carcinogenic potential of tamoxifen?
Robert H. Lurie Cancer Center, Northwestern University Medical School, Chicago, Illinois.
V C
VC
Jordan
M
M
Morrow
D000368:Aged; D000818:Animals; D001943:Breast Neoplasms / Q000188:drug therapy; D015197:Carcinogenicity Tests; D018736:DNA Adducts / Q000378:metabolism; D004334:Drug Administration Schedule; D016889:Endometrial Neoplasms / Q000139:chemically induced / Q000453:epidemiology; D005260:Female; D006801:Humans; D015994:Incidence; D008114:Liver Neoplasms, Experimental / Q000139:chemically induced; D051379:Mice; D008875:Middle Aged; D009369:Neoplasms / Q000139:chemically induced*; D016609:Neoplasms, Second Primary / Q000139:chemically induced; D051381:Rats; D013629:Tamoxifen / Q000008:administration & dosage / Q000009:adverse effects* / Q000378:metabolism
D018736:DNA Adducts; D013629:Tamoxifen